Metformin is the most commonly used pharmacological therapy for type 2 diabetes. We report a genome-wide association study for glycemic response to metformin in 1,024 Scottish individuals with type 2 diabetes with replication in two cohorts including 1,783 Scottish individuals and 1,113 individuals from the UK Prospective Diabetes Study. In a combined meta-analysis, we identified a SNP, rs11212617, associated with treatment success (n = 3,920, P = 2.9 × 10 −9 , odds ratio = 1.35, 95% CI 1.22-1.49) at a locus containing ATM, the ataxia telangiectasia mutated gene. In a rat hepatoma cell line, inhibition of ATM with KU-55933 attenuated the phosphorylation and activation of AMP-activated protein kinase in response to metformin. We conclude that ATM, a gene known to be involved in DNA repair and cell cycle control, plays a role in the effect of metformin upstream of AMP-activated protein kinase, and variation in this gene alters glycemic response to metformin.
In treating type 2 diabetes, metformin is recommended as first-line therapy in most national and international guidelines 1,2 . Despite the clinical use of metformin for over 50 years, its mechanism of action has not been fully elucidated. Although it is established that metformin activates AMP-activated protein kinase (AMPK) 3 by inhibition of the mitochondrial respiratory chain 4 , causing an increase in cellular AMP 5 , it remains uncertain whether AMPK is its sole therapeutic target.
There is considerable variability in glycemic response to metformin. No clinical phenotype usefully predicts response 6 , yet there has been little pharmacogenetic investigation of metformin, and no consistently replicated genetic variant has been associated with treatment response. We hypothesized that a GWAS approach could be applied to the glycemic response to metformin to gain insight into the mechanism of metformin's action in humans and to identify variants that may be useful clinically to predict efficacy or adverse outcome.
As part of the Wellcome Trust Case Control Consortium 2 study (WTCCC2), a GWAS of 15 complex traits and disorders, we carried out the first GWAS on metformin response in individuals with type 2 diabetes using a large Scottish observational genetic cohort (GoDARTS) of European ancestry. As our principal outcome phenotype, we used the ability to reduce HbA1c (the most widely used measure of medium-term glycemic control) in the first 18 months of therapy to below 7%, this being a key measure of success in many treatment algorithms. We included covariates shown to alter metformin response, such as baseline HbA1c level and creatinine clearance, in a logistic regression model (Supplementary Note). Full details of the cohorts and models used are available in the Online Methods, and baseline characteristics of the cohorts are shown in Supplementary Figure 1 and Supplementary Table 1. We genotyped the samples using the Affymetrix 6.0 microarray. After strict quality control steps, we analyzed 705,125 SNPs in 1,024 metformin-treated subjects (Supplementary Note). The resulting quantile-quantile plot is shown in Supplementary Figure 2 and the genomic inflation factor was 1.003. The Manhattan plot is shown in Supplementary Figure 3 . We found that 14 SNPs with P < 1 × 10 −6 mapped to a 340-kb strong linkage disequilibrium (LD) block on chromosome 11q22 (Fig. 1) . We observed no stronger association around this locus after imputing the data to the 2.2-million SNP HapMap II European CEU panel. SNPs at other loci that are potentially associated with metformin response did not achieve a P value lower than 1 × 10 −6 and were not followed up in the current study (Supplementary Table 2 ). The minor allele (C) of the most strongly associated SNP, rs11212617, had a frequency of 44% and was associated with treatment success (achieving an HbA1c below 7%) with an 1 1 8 VOLUME 43 | NUMBER 2 | FEBRUARY 2011 Nature GeNetics l e t t e r s allelic odds ratio of 1.64 (95% CI 1.37-1.99, P = 1.9 × 10 −7 ) ( Table 1 ).
The full model is shown in Supplementary Table 3a .
Our primary analysis used a binary treatment target as its endpoint. To check the robustness of this approach, we also analyzed treatment HbA1c as a quantitative trait in a linear regression analysis. In parallel with the primary analysis, we found that the C allele of rs11212617 was associated with lower treatment HbA1c (per-allele β = −0.18%, 95% CI −0.26 to −0.1, P = 1.8 × 10 −5 ) ( Table 1) .
We tested for replication of the rs11212617 association in two additional independent cohorts, replication 1 and replication 2 ( Table 1) . We genotyped rs11212617 in an independent GoDARTS cohort of 1,783 metformin-treated patients with type 2 diabetes (replication 1). The minor allele (C) of rs11212617 was associated with treatment success (allelic odds ratio (OR) = 1.21, 95% CI 1.05-1.38, P = 0.007) ( Table 1) . The second replication cohort was made up of 1,113 UK patients prospectively treated with metformin in the UK Prospective Diabetes (UKPDS) cohort (replication 2). The UKPDS was a prospective randomized clinical trial of intensive versus conventional treatment in individuals with type 2 diabetes. In the UKPDS, where, for technical reasons, we typed the proxy SNP rs609261 (r 2 = 0.997 with rs11212617 in 5,197 WTCCC2 controls), the minor allele was associated with treatment success (allelic OR = 1.37, 95% CI 1.10-1.72, P = 0.006) ( Table 1 ). The combined P value achieved a significance of P = 2.9 × 10 −9 for 3,920 metformin-treated patients ( Table 1) . The full models for each cohort are shown in Supplementary Table 3a-c. In the combined linear regression, each copy of the rs11212617 minor allele C was associated with 0.11% lower absolute treatment HbA1c (P = 6.6 × 10 −7 ) ( Table 1) .
Metformin can be used as monotherapy alone or can be added in to other therapies. However, current prescribing practice is for metformin to be used as the first-line treatment, so we therefore analyzed the monotherapy subgroup separately. Most of the association signal at rs11212617 with metformin response for the full group arose from the monotherapy subgroup (Supplementary Table 4) . In a meta-analysis of this monotherapy group (n = 2264), the combined OR for treatment success was 1.42 (95% CI 1.26-1.62, P = 4 × 10 −8 ). To assess the clinical impact of rs11212617, we studied the UKPDS cohort that was randomly assigned to metformin monotherapy (n = 284) and followed up prospectively, and thus was therefore not prone to treatment selection bias. In this subgroup, the 19% of patients with two copies of the C allele at rs11212617 had a 3.3-fold greater likelihood of achieving an HbA1c ≤ 7%. This equates to a model-adjusted difference in treatment HbA1c of 0.61% between those who have the CC alleles versus those who have the AA alleles at this SNP. Adding genotype to the full linear regression model in this UKPDS group randomized to metformin increased the variance in the treatment HbA1c explained by the model from 27.5% to 30% (P = 0.007).
To ensure that the genotypic effect on metformin response was not related to an effect on HbA1c per se and to assess the association with fasting insulin and homeostatic model assessment-derived insulin resistance (HOMA-IR), we analyzed summary statistics for rs11212617 from the MetaAnalyses of Glucose and Insulin-related traits Consortium (MAGIC) 7 . We found no association of rs11212617 with HbA1c (P = 0.82), HOMA-IR (P = 0.99) and fasting insulin (P = 0.73) in at least 35,914 nondiabetic individuals (Supplementary Note). We found no association between baseline HbA1c and rs11212617 in the GoDARTS discovery or replication dataset. In addition, there was no association of rs11212617 with lipid parameters, blood pressure, height, weight, body mass index, adiponectin and leptin in up to 6,148 Scottish controls (Supplementary Table 5 ), nor with type 2 diabetes risk in a case-control study of 5,788 Scottish GoDARTS cases with type 2 diabetes and 6,357 non-diabetic Scottish GoDARTS controls (P = 0.64).
rs11212617 falls within a large block of LD that includes CUL5, ACAT1, NPAT, ATM, C11orf65, KDELC2 and EXPH5. Of these, ATM was considered a possible candidate gene for several reasons. First, homozygous loss of function mutations in ATM cause ataxia telangiectasia (A-T; MIM208900), which is a neurodegenerative disorder characterized by loss of muscle coordination and progressive ataxia, radiosensitivity, immunodeficiency and a predisposition to cancer 8 . Additionally, individuals with A-T have been reported to have marked insulin resistance and an increased risk of diabetes 9,10 . Second, previous laboratory reports suggest that activation or inhibition of ATM alters AMPK activation [11] [12] [13] . None of the other genes at the locus have been reported to be associated with diabetes or insulin action.
ATM encodes a 370-kDa protein that is a serine/threonine protein kinase of the atypical phosphoinositide 3-kinase-related protein kinase (PIKK) family. ATM is activated by double-stranded DNA breaks and acts to induce cell-cycle arrest and to facilitate DNA repair 14 . To investigate if ATM was the causal gene affecting the glycemic response to metformin, we studied the effects of a selective ATM inhibitor, KU-55933, on the activation of AMPK by metformin in rat hepatoma (H4IIE) cells. The reference allele for rs11212617 was the A allele. For the UKPDS samples, results are for rs609261, which was genotyped in this cohort due to technical difficulties but which was a proxy for rs11212617 (r 2 = 0.997 in WTCCC2 controls). The logistic regression analysis shows the allelic odds ratio for the ability to achieve a treatment HbA1c ≤ 7% in the 18 months after starting metformin. The linear regression analysis shows the per-allele increase in treatment HbA1c in the treatment period after starting metformin. Covariates included in the model were baseline HbA1c, the gap between treatment-starting HbA1c and baseline HbA1c, dose, adherence, creatinine clearance and treatment group. Full models are shown in supplementary table 3.
l e t t e r s by stimuli other than metformin 11-13 . We conclude that ATM acts upstream of AMPK and is required for a full response to metformin. ATM is also reported to be involved in insulin signaling and pancreatic β-cell dysfunction, both of which may influence metformin action. Apoe −/− mice heterozygous for loss of Atm function were insulin resistant as compared to Apoe −/− mice with normal Atm (ref. 15); however, mice lacking Atm developed diabetes due to β-cell dysfunction 16 .
We assessed the potential functionality of all the 98 SNPs in strong LD (r 2 > 0.8 according to the HapMap CEU panel) with rs11212617 ( Supplementary Table 6 ). rs228589, which is in intron 1 of NPAT, is in a predicted promoter of ATM (ref. 17) . Two SNPs, rs227092 and rs4585, are located in the ATM 3′ untranslated region (UTR). The variant rs4585 lies 24 bp downstream of a polyadenylation site and is predicted to alter the efficiency of polyadenylation (Supplementary Table 6 ). The 3′ UTR of ATM is among the longest known mammalian 3′ UTRs and has been suggested to influence ATM mRNA translation, allowing rapid response to stimuli at the posttranscriptional level 18, 19 .
Type 2 diabetes is associated with increased cancer risk, and an overlap between genes predisposing to prostate cancer and type 2 diabetes has been previously described 20 . Metformin has been shown in epidemiological studies to be associated with decreased cancer risk 21 and to decrease tumor burden in Pten-deficient mice 22 . Activation of AMPK by metformin requires the known tumor suppressor LKB1. In this study, the implication of ATM, a gene known to be involved in DNA repair and cancer, in the glycemic response to metformin establishes a further link between cancer pathways, type 2 diabetes and metformin activation of AMPK.
In this study, we established the utility of a GWAS approach to study the pharmacogenomics of metformin response and the utility of large genetics resources linked to routinely collected clinical data for pharmacogenetic studies. We identified the first robustly replicated common genetic variant to be associated with metformin response. Although this observation may not be of immediate clinical utility, as it explains only 2.5% of the variance in metformin response, this study is an example of how GWAS can be applied to pharmacogenomic models to identify new pathways and mechanisms, and it has established an unexpected link between glucose homeostasis and the DNA damage response.
MeThoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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oNLINe MeThoDS
Samples. The discovery cohort and first replication cohort were both ascertained from the Diabetes Audit and Research Tayside Study (DARTS) 23 . Validated prescribing data, biochemistry data and clinical phenotypes dating back to 1992 can be retrieved from central databases for all the DARTS subjects. Prospective longitudinal data were also collected on these individuals. Since October 1997, all individuals with diabetes from DARTS have been invited to give written informed consent for DNA collection as part of the Wellcome Trust United Kingdom Type 2 Diabetes case-control collection. As of June 2009, 8,000 cases and 7,000 controls of European ancestry have participated in this Genetics of DARTS (GoDARTS) study. As part of the WTCCC2, 4,134 GoDARTS cases were selected primarily for a GWAS of statin response and also for a study of response to oral hypoglycemic agents (OHA). Following the WTCCC2 genotyping quality control (see below), 1,024 individuals were identified who were initiated on metformin and had a definable metformin response (discovery cohort). Of the GoDARTS cases not in the WTCCC2 discovery cohort, metformin response could be defined in 1,783 individuals and these individuals were used for the first round replication.
For the second replication cohort, we used individuals with type 2 diabetes either randomized to metformin or treated with metformin as per protocol in the UK Prospective Diabetes Study (UKPDS) 24 . A total of 1,113 European patients, who were exposed to metformin and passed the genotyping quality control, were identified in the UKPDS cohort. These individuals were either primarily randomized to metformin (n = 284), were randomized second line as add-in to sulfonylureas (n = 231), or had metformin added to sulfonylurea per protocol for symptomatic hyperglycemia or when fasting glucose was greater than 15 mmol/l (n = 598).
Phenotypes. Because over 92% of the OHA prescriptions issued in the GoDARTS cohort were either metformin (51.4%) or sulfonylurea (41.2%), we focused on two treatment schemes: metformin monotherapy (metformin added following failure of dietary control) or dual therapy (metformin added to stable sulfonylurea treatment).
Following initiation of oral hypoglycemic agents in individuals with type 2 diabetes, there was an initial reduction in HbA1c followed by a gradual deterioration. This was seen in both the UKPDS study and other diabetes trials, such as ADOPT 25 . The gradual deterioration in HbA1c reflects both drug efficacy (or inefficacy) to control HbA1c and also the underlying diabetes progression. To target the drug response alone, we focused on the first 18 months of metformin therapy to minimize the response window but to ensure minimal exclusion due to lack of HbA1c data.
In this observational study, the patient's physician was treating to achieve an HbA1c target, which, over the majority of the study period, would have been 7%. We therefore defined our primary drug response phenotype as a dichotomous trait of treatment success, which was the ability to achieve an HbA1c below 7% in the first 18 months of treatment, with censoring if the diabetes therapy was changed before this time. Our secondary analysis took the quantitive phenotype as treatment HbA1c, which was the lowest HbA1c observed between 1 and 18 months after metformin treatment or before a change in therapy (cessation of metformin or addition of further oral hypoglycaemic therapy).
The two phenotypes were modeled with multiple linear or logistic regression using the same set of covariates, which included baseline HbA1c, adherence, daily dose, creatinine clearance, baseline gap and treatment group. More details of the models and covariates are provided in the Supplementary Note.
In UKPDS, HbA1c was measured yearly, and the HbA1c measure taken closest to one year after commencing metformin treatment was used as the treatment HbA1c. In the cases randomized to metformin, this would have been approximately one year after starting metformin; in those cases starting metformin as per protocol due to hyperglycemia, the time between starting metformin and the treatment HbA1c was variable, so an additional covariate (treatment gap) was included in the model. Treatment success was defined as a treatment HbA1c ≤ 7%. Other covariates included were the same as for the GoDARTS models, except adherence and dose were not included here due to missing data.
GWAS genotyping and quality control. Samples were genotyped at Affymetrix's service laboratory on the Genome-Wide Human SNP Array 6.0.
Genotype data quality control was done using the standard protocol that was established for the WTCCC2 studies 26 (Supplementary Note). Specifically, a concordance check was performed on 116 SNPs from 1,779 individuals that overlapped between this GWAS data and the WTCCC1 T2D case control study 27 . Based on the overall concordance rate of 99.73%, individuals with more than 10% discordance were removed from the current study. After such stringent quality control filtering, the clean dataset included 705,125 autosomal SNPs on 3,736 samples, of whom 1,024 had a definable metformin response.
Replication genotyping. In the first round replication, following assay optimization of the top two SNPs from the GWAS (rs11212617 and rs624366, r 2 = 0.997 in 3,736 GoDARTS samples), rs11212617 had better genotyping performance and was genotyped by the standard TaqMan-based allelic discrimination method (Applied Biosystems) in the whole GoDARTS cohort, which included 7,000 non-diabetic controls. The overall call rate was 98.3%, with a concordance rate of 99.9% to the GWAS genotypes. There was no deviation from Hardy Weinberg equilibrium (P = 0.44). The minor allele C had a frequency of 43.9% in the 1,783 individuals in the GoDARTS replication sample.
TaqMan was also used for genotyping the UKPDS replication sample. Following optimization of four highly correlated SNPs (rs11212617 and rs624366, as well as two proxies, rs609261 and rs2345801) in a subset of UKPDS samples, rs609261 was selected and genotyped based on better genotyping performance than the other SNPs. rs609261 is almost a perfect proxy for rs11212617 (r 2 = 0.997 in 5,197 WTCCC2 controls) and as such, results are presented as for rs11212617 in the UKPDS cohort. Genotyping of all available UKPDS DNA (n = 3400) was carried out in duplicate using standard conditions. Discrepancy between the duplicate genotyping runs was 0.4%, and only samples for which the duplicate genotypes were concordant were analyzed. The final UKPDS replication cohort included 1,113 individuals of European ancestry, and the minor allele frequency was 42.1%, with no deviation from Hardy-Weinberg equilibrium (P = 0.98).
Statistical analysis. Logistic and linear regression modeling was performed with PLINK and SNPTEST 28, 29 assuming an additive genetic model. All the results presented were unadjusted for population stratification, as genomic inflation factors of 1.003 and 0.998 were observed in the logistic and linear regression analyses, respectively.
Data from the discovery cohort were also imputed to the HapMap II CEU panel of 2.2 million SNPs with the program IMPUTE and were tested for association with SNPTEST, taking into account the imputed genotype probabilities 30 .
As the two SNPs, rs11212617 and rs609261, that were genotyped in the GoDARTS sample and the UKPDS sample, respectively, were in near complete LD (r 2 = 0.997), we directly combined the single marker association test results from the discovery cohort and the two replication cohorts with the inverse variance fixed effect method, as implemented in the R package of GenABEL 31 .
Functional studies. KU-55993 is a cell-permeable ATP-competitive inhibitor of ATM (half maximal inhibitory concentration (IC 50 ) = 13 nM, K i = 2.2 nM) with selectivity over other PIKK-family kinases (IC 50 = 2.5 µM, IC 50 = 9.3 µM and IC 50 = 16.6 µM for DNA-PK, mTOR and PI 3-K, respectively; IC 50 > 100 µM for PI 4-K and ATR) 32 . It is reported to have little activity toward a panel of 70 conventional serine/threonine kinases. It has been shown to inhibit ATM-dependent cellular protein phosphorylation following ionizing radiation and sensitizes cells that express wildtype ATM (but not mutant ATM) to the cytotoxic effects of ionizing radiation and DNA-damaging agents 33, 34 .
H4IIE cells were cultured in Dulbecco's modified Eagle's medium containing 5% (v/v) FBS to 80% confluence. For AMPK assays, cells were pretreated with 10 µM KU-55933 (for 30 min) before treatment with various concentrations of metformin for 1 h. Lysates were prepared (rapid lysis method 35 ) , centrifuged (at 4 °C for 10 min and 21,000 × g), and the supernatants were frozen for later analysis. AMPK activity was assayed in immunoprecipitates as described 35 using the AMARA peptide 36 .
To establish that the change in AMPK activity was due to the regulation of phosphorylation of AMPK and that this translated into changes in substrate phosphorylation, we used protein blotting to compare the phosphorylation status of Thr172 of AMPK and Ser79 of ACC (a well characterized marker of AMPK activation). In both cases, metformin-induced phosphorylation was partially reduced (Fig. 3) .
For these experiments, H4IIE cells were cultured to 80% confluence as above, then serum starved for 16 h, pretreated with KU-55933 or vehicle (DMSO) for 1 h and then treated for 3 h with or without metformin. They were then harvested as described above. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose. The membrane was blocked in TBST containing 5% (wt/v) milk for 1 h and then incubated overnight at 4 °C with phosphoThr172-AMPK antibody (Cell Signaling), phospho-Ser79 ACC antibody (Cell Signaling) or β-actin antibody (Sigma). Membranes were washed in TBST, incubated with goat anti-rabbit IgG conjugated to horseradish peroxidase (Pierce) and then washed again in TBST. The membrane was then developed using an ECL Western Blotting Detection Kit (Amersham Biosciences) before exposure to X-ray film (Thermo Scientific).
